We did get real news on Monday but it didn't come from Clinuvel. Clinuvel had two potential competitors for EPP treatment that many believed were less than 2-3 years away from being approved. Both Bitopertin (Disc) and Dersimelagon (Tanabe) Phase II & Phase III trials failed in the past few months. Both may choose to start over or they may abandon their hopes to one day treat EPP patients altogether. Clinuvel has a monopoly on EPP treatment for many years to come. That is news by itself.
EPP Monomply News
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.87 |
Change
-0.090(0.64%) |
Mkt cap ! $694.3M | |||
| Open | High | Low | Value | Volume |
| $14.00 | $14.07 | $13.84 | $834.5K | 60.01K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1134 | $13.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.89 | 127 | 1 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| CUV (ASX) Chart |